NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

CompletedN/A

Sponsor: The Lymphoma Academic Research Organisation

Conditions: Follicular Lymphoma

Countries: France

Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option which can induce long-term responses in refractory and relapsed B cell lymphoma patients. However, the factors determining the quality and duration of responses are poorly understood.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

patients who participate to CELESTIMO study (NCT04712097)

Locations (9)

Bayonne, France
Lille, France
Marseille, France
Montpellier, France
Nantes, France
Nîmes, France
Paris, France
Poitiers, France
Rennes, France